Group 1 - The stock price of Lidman is reported at 8.54 yuan, down 0.35 yuan from the previous trading day, with a decline of 3.94% [1] - The highest intraday price reached 8.92 yuan, while the lowest dipped to 8.53 yuan, with a trading volume of 364,600 shares and a transaction amount of 318 million yuan [1] - Lidman operates in the medical device industry, focusing on in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials, primarily used in clinical testing and food safety detection [1] Group 2 - For the first half of 2025, the company reported total operating revenue of 160 million yuan, a year-on-year decrease of 14.80%, and a net loss attributable to shareholders of 4.2452 million yuan [1] - The decline in performance is mainly attributed to industry procurement policies, the splitting of testing packages, and intensified market competition, with core business revenue from in vitro diagnostic reagents dropping by 28.13% [1] - However, revenue from diagnostic instruments and accessories increased to 22.7416 million yuan, reflecting a year-on-year growth of 106.73% [1] Group 3 - On August 27, the net outflow of main funds was 46.4047 million yuan, accounting for 1% of the circulating market value [1] - Over the past five days, the net outflow of main funds totaled 189.5546 million yuan, representing 4.09% of the circulating market value [1]

Core Viewpoint - The board of directors of Beijing Lideman Biochemical Co., Ltd. has approved the 2025 semi-annual report, confirming that it accurately reflects the company's actual situation without any false statements or omissions [1][2]. Group 1 - The sixth board of directors held its fifth meeting on August 26, 2025, via telecommunication, with all necessary notifications sent to the board members [1]. - The meeting was attended by all seven directors, and the presence of supervisors and senior management was noted, ensuring compliance with relevant laws and regulations [1]. - The board unanimously approved the proposal regarding the full and summary report for the first half of 2025, with a voting result of 7 votes in favor, 0 against, and 0 abstentions [2]. Group 2 - The company asserts that the 2025 semi-annual report and its summary were prepared in strict accordance with applicable laws, regulations, and guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange [1]. - The report is claimed to be true, accurate, and complete, reflecting the company's actual conditions without any misleading statements or significant omissions [1].

Core Points - The company held its sixth supervisory board's fifth meeting on August 26, 2025, to review and approve the 2025 semi-annual report and its summary [1][2] - The supervisory board confirmed that the report complies with relevant laws, regulations, and the company's internal rules, ensuring the information is true, accurate, and complete [1] - The voting results showed unanimous approval with 3 votes in favor, 0 against, and 0 abstentions for the proposal [2] Summary by Sections - **Meeting Details** - The meeting was conducted via telecommunication and attended by three supervisors, with the chairman presiding [1] - The meeting adhered to the requirements of the Company Law of the People's Republic of China and the company's articles of association [1] - **Report Review** - The supervisory board reviewed the 2025 semi-annual report and its summary, concluding that the content accurately reflects the company's operational and financial status [1] - The report was found to meet the requirements set by the Shenzhen Stock Exchange and the China Securities Regulatory Commission [1] - **Voting Outcome** - The proposal regarding the semi-annual report was passed with a unanimous vote of 3 in favor [2]

Group 1 - The company announced that its sixth supervisory board's fifth meeting approved the proposal for the full text and summary of the 2025 semi-annual report [2]

Core Viewpoint - Lideman announced the approval of the full text and summary of the 2025 semi-annual report by its sixth board of directors at the fifth meeting [2] Group 1 - The announcement was made on the evening of August 26 [2] - The decision was made during a board meeting [2] - The report pertains to the company's performance for the first half of 2025 [2]

智通财经APP讯，利德曼(300289.SZ)发布2025年半年度报告，该公司营业收入为1.6亿元，同比减少 14.80%。归属于上市公司股东的净亏损为424.52万元。归属于上市公司股东的扣除非经常性损益的净亏 损为1055.26万元，同比扩大191.60%。基本每股亏损为0.0078元。 ...

Group 1 - Lidman (SZ 300289, closing price: 8.89 yuan) announced on August 26 that its sixth fifth board meeting was held via communication method, discussing the proposal for the full text and summary of the 2025 semi-annual report [1] - For the year 2024, Lidman's revenue composition is as follows: 90.84% from the biopharmaceutical industry, 8.98% from property leasing, and 0.17% from services [1] - As of the report date, Lidman's market capitalization is 4.8 billion yuan [1] Group 2 - The pet industry is experiencing a significant boom, with a market size of 300 billion yuan, leading to a surge in stock prices of related listed companies [1]

Core Viewpoint - Lideman (300289) reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved operating revenue of 160 million yuan in the first half of 2025, representing a year-on-year decrease of 14.80% [1] - The net profit for the same period was -4.2452 million yuan, reflecting a substantial year-on-year decline of 800.43% [1] - Basic earnings per share were reported at -0.0078 yuan [1] - The weighted average return on equity (ROE) stood at -0.26% [1]

Core Viewpoint - Lideman (300289.SZ) reported a decline in revenue and an increase in net losses for the first half of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first half of 2025 was 160 million yuan, representing a year-on-year decrease of 14.80% [1] - The net loss attributable to shareholders of the listed company was 4.2452 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 10.5526 million yuan, which expanded by 191.60% year-on-year [1] - The basic loss per share was 0.0078 yuan [1]

证券代码：300289 证券简称：利德曼 公告编号：2025-038 北京利德曼生化股份有限公司 2025年半年度报告披露提示性公告 北京利德曼生化股份有限公司 董 事 会 2025 年 8 月 26 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司（以下简称"公司"）于 2025 年 8 月 26 日召开第六届董事会第五次会议、第六届监事会第五次会议，审 议通过了《关于 2025 年半年度报告全文及摘要的议案》。 为使投资者全面了解本公司的经营成果、财务状况及未来发展规 划，公司《2025 年半年度报告》及《2025 年半年度报告摘要》于 2025 年 8 月 27 日在中国证监会指定的创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上披露，敬请投资者注意查阅！ 特此公告。 ...